Products /
Primary Antibodies /
PPP1R14A/CPI-17 (F1I6X) Rabbit Monoclonal Antibody

PPP1R14A/CPI-17 (F1I6X) Rabbit Monoclonal Antibody #66256

Filter:

Product Specifications

REACTIVITY	H M R
SENSITIVITY	Endogenous
MW (kDa)	19, 17
Source/Isotype	Rabbit IgG

Application Key:

WB-Western Blotting
IP-Immunoprecipitation
IHC-Immunohistochemistry
IF-Immunofluorescence

Species Cross-Reactivity Key:

H-Human
M-Mouse
R-Rat

Product Information

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:200
Immunohistochemistry (Paraffin)	1:50 - 1:200
Immunofluorescence (Immunocytochemistry)	1:1000 - 1:4000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

PPP1R14A/CPI-17 (F1I6X) Rabbit Monoclonal Antibody recognizes endogenous levels of total PPP1R14A/CPI-17 protein. This antibody does not cross-react with PPP1R14B/PHI-1. This antibody detects a 70 kDa protein of unknown identity in some cell lines. Non-specific staining was observed at the apical membrane of normal human colon epithelium by immunohistochemistry. Immunocytochemistry reactivity is human only.

Species Reactivity:

Human, Mouse, Rat

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human PPP1R14A/CPI-17 protein.

Background

Protein kinase C-potentiated inhibitor protein of 17 kDa (CPI-17), encoded by the protein phosphatase 1 (PP1) regulatory subunit 14A (PPP1R14A) gene, promotes smooth muscle contraction by inhibiting the activity of the PP1 holoenzyme, smooth muscle myosin phosphatase (MYPT1) (1). CPI-17 belongs to a family of proteins, including PPP1R14B/PHI-1, PPP1R14C/KEPI, and PPP1R14D/GEPI, that each specifically inhibits a subset of PP1 holoenzymes (1). CPI-17 expression, localization, and enzymatic activity are driven by a combination of epigenetic and posttranslational modifications, all of which have downstream effects on PP1-dependent cellular processes. CPI-17 is a substrate for PKC, ROCK1, ZIPK, MST3/MST4, and CaMKII, with established phosphorylation target sites at Ser12, Thr38, and Ser130 (1-6). Additional putative phosphorylation sites with as yet undefined upstream kinases may be regulated by luteinizing hormone signaling in rodent ovary (7). CPI-17 is translocated from the cytoplasm to the nucleus via the importin complex, and phosphorylation of CPI-17 at Ser12 disrupts the N-terminal nuclear localization signal (8). Nuclear CPI-17 inhibits PP1-mediated dephosphorylation of histone H3, and CPI-17 protein knockdown by siRNA decreased PANC-1 pancreatic carcinoma cell proliferation (8). Thr38 phosphorylation increases CPI-17 inhibitory activity 1,000-fold, and can be induced in vitro by upstream kinase agonists (9,10). In a pan-cancer analysis, PPP1R14A mRNA and protein expression were found to be decreased across a wide variety of cancer types, including breast, colon, and ovarian cancers, kidney renal clear cell carcinoma, lung adenocarcinoma, and uterine corpus endometrial carcinoma (11). The pan-cancer expression profile correlated with increased PPP1R14A promoter methylation (11). Increased PPP1R14A gene silencing by DNA methylation was also observed in nearly 80% of non-Hodgkin lymphoma patient samples relative to control B lymphocytes (12).

Alternate Names

17 kDa PKC-potentiated inhibitory protein of PP1; 17-KDa protein; 17-kDa PKC-potentiated inhibitory protein of PP1; 17-KDa protein; CPI-17; CPI17; PKC-potentiated inhibitory protein of PP1; PP14A; PPP1INL; PPP1R14A; Protein kinase C-potentiated inhibitor protein of 17 kDa; protein phosphatase 1 regulatory inhibitor subunit 14A; Protein phosphatase 1 regulatory subunit 14A; protein phosphatase 1, regulatory (inhibitor) subunit 14A

Database Links

UniProt ID: Q96A00

Entrez-Gene Id: 94274

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

For Research Use Only. Not for Use in Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

All other trademarks are the property of their respective owners. Visit our Trademark Information page.